NeuroOne Medical Technologies Corporation (NMTC) announced the publication of a peer-reviewed case series detailing clinical experience with its OneRF Ablation System, the first FDA-cleared system for nervous tissue ablation using the same sEEG electrode for both diagnosis and therapy. The study, published in Stereotactic and Functional Neurosurgery, reports on four patients with drug-resistant epilepsy treated at a leading U.S. epilepsy center. The authors described the procedure as safe and easy to integrate into existing stereotactic neurosurgical workflows, allowing treatment in the operating room or at the patient’s bedside in the epilepsy monitoring unit. The technology enabled RF ablation without removing or repositioning already implanted sEEG electrodes, while real-time temperature monitoring allowed precise, controlled lesions, minimizing risk to surrounding brain structures. No adverse events occurred, and all four patients experienced reductions in seizure burden. The procedure also provided information that guided subsequent surgical decision-making, underscoring its potential as a diagnostic and prognostic tool. The authors noted that this development represents a significant advancement in the work-up of patients with intractable epilepsy undergoing sEEG for invasive evaluation.
The OneRF Ablation System is NeuroOne’s first device with a therapeutic indication and its third FDA 510(k)-cleared device. NeuroOne now offers a full line of thin film electrode technology for diagnostic brain mapping and RF ablation using the same sEEG electrode. The company estimates the combined sEEG and brain ablation market at least $200 million worldwide, with potential for multifold growth based on large addressable patient populations with unmet clinical needs. The publication is accessible via PubMed. This article is distributed by NeuroOne for educational purposes; the views expressed are those of the author and do not necessarily reflect the position of NeuroOne.
NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care and outcomes for patients with neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes. The company is also engaged in research and development for drug delivery and spinal cord stimulation programs. For more information, visit nmtc1.com.
